Carol Tweed, MD
Medical Oncology · Annapolis, MDNPI 1649219155
Payments from drug & device makers
Across 224 payments — averaging $4984.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$426K
- Astrazeneca UK Limited$197K
- Eli Lilly$196K
- Tolmar, Inc.$68K
- Seagen Inc.$62K
- Novartis$54K
- plus $113K from 24 others
Across 1 payment — averaging $18,246 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$18K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $426,070 |
| Astrazeneca UK Limited | 6 | $196,875 |
| Eli Lilly | 11 | $195,952 |
| Tolmar, Inc. | 42 | $68,002 |
| Seagen Inc. | 38 | $62,335 |
| Novartis | 11 | $54,473 |
| G1 Therapeutics, Inc. | 14 | $45,913 |
| Genentech, Inc. | 7 | $36,979 |
| Gilead | 22 | $14,553 |
| Pfizer | 3 | $5,176 |
| Merck | 5 | $3,484 |
| Sanofi | 1 | $1,596 |
| Daiichi Sankyo Inc. | 3 | $1,417 |
| Macrogenics, Inc. | 1 | $1,375 |
| Genentech USA, Inc. | 2 | $1,123 |
| Athenex Pharmaceutical Division, LLC | 2 | $600 |
| GSK | 5 | $165 |
| Johnson & Johnson | 4 | $65 |
| AbbVie | 2 | $53 |
| Bristol Myers Squibb | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 1 | $34 |
| Azurity Pharmaceuticals, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Caris MPI, Inc. | 1 | $25 |
| Puma Biotechnology, Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $13 |
How this compares
$1,116,488 in reported general payments places this provider in the 75th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Annapolis
- James DoroshowBethesda$177.3M
- Dung leBaltimore$18.7M
- Helen ChenBethesda$14M
- Stephanie GaillardBaltimore$12.2M
- Ashraf BadrosBaltimore$7.2M
- William SharfmanLutherville$7.2M
- Patrick BrownBaltimore$6.6M
- Nilofer AzadBaltimore$6.5M
- Jean Hoffman-CensitsBaltimore$5.7M
- Ranee MehraBaltimore$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.